CLINICAL AND IMMUNOLOGICAL EFFICACY OF LICOPID FOR DISEASES IN NEWBORNS
This article provides state-of-the-art ideas about the specifics of immune responses in full-term and premature newborns. Proprietary data are given on the influence of glucosaminylmuramyl dipeptide (GMDP) (Licopid, PEPTEK, ZAO, Russia) on functional activity of neutrophil granulocytes in vitro and in vivo in newborns with respiratory distress syndrome, various types of intrauterine growth retardation, diabetic fetopathy. Clinical implications of immunotropic effects of Licopid ® involved significant decrease in frequency of neonatal and ventilator-associated pneumonia, duration of artificial lung ventilation, and in general resulted in improvement of treatment quality and pharmacoeconomic characteristics.